A Phase 3 interventional study of dupilumab and Placebo in Moderate to Severe Atopic Hand and Foot Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 48 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-12-22.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients with atopic hand and foot dermatitis.
The secondary objectives of the study are:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion / exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered subcutaneously (SC) once every 2 weeks (Q2W), following a loading dose on Day 1
Drug: dupilumab
Administered SC Q2W, following a loading dose on Day 1
Drug: Placebo
Solution for subcutaneous (SC) injection administration
Also known as: DUPIXENT®, REGN668, SAR231893
Solution for SC injection administration
Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16
IGA is an assessment scale used to determine severity of hand and foot AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Higher score is indicative of more severe disease.
Time frame: At week 16
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus Numerical Rating Scale (NRS) of ≥4 Points From Baseline to Week 16
Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
Time frame: Baseline to week 16
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥3 From Baseline to Week 16
Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
Time frame: Baseline to week 16
Percent Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS
Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
Time frame: Baseline to week 16
Percent Change in Modified Total Lesion Sign Score (mTLSS) for Hand/Foot Lesions From Baseline to Week 16
mTLSS combines an evaluation of hand and foot eczema lesions severity; scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 18 (more serious disease).
Time frame: Baseline to Week 16
Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pain NRS
Pain NRS Scale is an assessment tool used to report the intensity of a participant's pain. Participants will select the number between 0 and 10 that fits best to their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain possible).
Time frame: Baseline to week 16
Mean Change From Baseline to Week 16 in Weekly Average of Daily Sleep NRS
Sleep NRS is an 11-point scale (0 to 10) in which 0 indicates worst possible sleep while 10 indicates best possible sleep.
Time frame: Baseline to week 16
Change From Baseline to Week 16 in Percent Surface Area of Hand and Foot Involvement With Atopic Dermatitis (AD)
Time frame: Baseline to week 16
Percent Change From Baseline to Week 4 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS
Pruritus NRS is an assessment tool that is used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
Time frame: Baseline to week 4
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥4 From Baseline to Week 4
Pruritus NRS is an assessment tool that is used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
Time frame: Baseline to week 4
Percent Change From Baseline to Week 16 in Hand Eczema Severity Index (HECSI) Score in Participants With Hand Dermatitis
For participants with hand dermatitis HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The range for the combined HECSI score is from 0 to 360 (5x6x3x4).
Time frame: Baseline to week 16
Percentage of Participants With HECSI-75 at Week 16
HECSI-75 is defined as HECSI score has ≥75% improvement from baseline for participants with hand dermatitis.
Time frame: At week 16
Percentage of Participants With HECSI-50 at Week 16
HECSI-50 is defined as HECSI score has ≥50% improvement from baseline, for participants with hand dermatitis.
Time frame: At week 16
Percentage of Participants With HECSI-90 at Week 16
HECSI-90 is defined as HECSI score has ≥90% improvement from baseline for participants with hand dermatitis.
Time frame: At week 16
Change From Baseline to Week 16 in Quality of Life in Hand Eczema Questionnaire (QOLHEQ)
For participants with hand dermatitis, QOLHEQ is an instrument to assess disease specific Health Related Quality of Life (HRQOL) in those suffering from hand eczema. QOLHEQ overall scoring ranges as follows: 0 (best score) to 117 (worst score).
Time frame: Baseline to week 16
Mean Change From Baseline to Week 16 in Work Productivity and Impairment (WPAI) and Classroom Impairment Questionnaire (CIQ)
WPAI + CIQ is a self-administered instrument used to capture the impairment to work productivity/classroom impairment and activity due to atopic hand and foot dermatitis. The WPAI+CIQ yields 4 types of scores: absenteeism, presenteeism, work/classroom productivity loss and activity impairment. All scores range from 0 to 100% with 100% indicating total work/classroom productivity impairment and 0 no impairment at all.
Time frame: Baseline to week 16
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 16
Time frame: Through week 16
Trough Concentration of Functional Dupilumab in Serum at Various Time Points
Time frame: Up to week 28
Number of Participants With Treatment-Emergent (TE) Anti-Drug Antibody (ADA)
Time frame: Up to week 28
Number of Participants With Treatment-Emergent ADA by Maximum Titer Category
Time frame: Up to Week 28
| Milestone | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Started | 66 | 67 |
| Completed | 53 | 60 |
| Not completed | 13 | 7 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 7 | 6 |
| Withdrew: Lack of efficacy | 3 | 1 |
IGA is an assessment scale used to determine severity of hand and foot AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Higher score is indicative of more severe disease.
| Percentage of participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 | 16.7 | 40.3 |
Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
| Percentage of participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus Numerical Rating Scale (NRS) of ≥4 Points From Baseline to Week 16 | 13.6 | 52.2 |
Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
| Percentage of participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥3 From Baseline to Week 16 | 16.7 | 61.2 |
Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
| Percentage of change | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS | -26.2 (-38.0 to -14.4) | -62.9 (-74.6 to -51.3) |
mTLSS combines an evaluation of hand and foot eczema lesions severity; scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 18 (more serious disease).
| Percentage of change | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change in Modified Total Lesion Sign Score (mTLSS) for Hand/Foot Lesions From Baseline to Week 16 | -31.0 (-42.6 to -19.4) | -69.4 (-80.9 to -58.0) |
Pain NRS Scale is an assessment tool used to report the intensity of a participant's pain. Participants will select the number between 0 and 10 that fits best to their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain possible).
| Score on a scale | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pain NRS | -1.93 ± 0.432 | -4.66 ± 0.426 |
Sleep NRS is an 11-point scale (0 to 10) in which 0 indicates worst possible sleep while 10 indicates best possible sleep.
| Score on a scale | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Mean Change From Baseline to Week 16 in Weekly Average of Daily Sleep NRS | -0.00 ± 0.335 | 0.88 ± 0.334 |
| Percentage of hand and foot BSA | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Change From Baseline to Week 16 in Percent Surface Area of Hand and Foot Involvement With Atopic Dermatitis (AD) | -10.01 ± 2.388 | -16.70 ± 2.375 |
Pruritus NRS is an assessment tool that is used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
| Percentage of change | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change From Baseline to Week 4 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS | -25.6 (-36.3 to -15.0) | -47.2 (-57.7 to -36.6) |
Pruritus NRS is an assessment tool that is used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).
| Percentage of participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥4 From Baseline to Week 4 | 9.1 | 34.3 |
For participants with hand dermatitis HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The range for the combined HECSI score is from 0 to 360 (5x6x3x4).
| Percentage of change | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change From Baseline to Week 16 in Hand Eczema Severity Index (HECSI) Score in Participants With Hand Dermatitis | -33.8 ± 42.21 | -68.2 ± 25.56 |
HECSI-75 is defined as HECSI score has ≥75% improvement from baseline for participants with hand dermatitis.
| Percentage of participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percentage of Participants With HECSI-75 at Week 16 | 21.5 | 46.9 |
HECSI-50 is defined as HECSI score has ≥50% improvement from baseline, for participants with hand dermatitis.
| Percentage of participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percentage of Participants With HECSI-50 at Week 16 | 30.8 | 75.0 |
HECSI-90 is defined as HECSI score has ≥90% improvement from baseline for participants with hand dermatitis.
| Percentage of participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percentage of Participants With HECSI-90 at Week 16 | 9.2 | 18.8 |
For participants with hand dermatitis, QOLHEQ is an instrument to assess disease specific Health Related Quality of Life (HRQOL) in those suffering from hand eczema. QOLHEQ overall scoring ranges as follows: 0 (best score) to 117 (worst score).
| Score on a scale | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Change From Baseline to Week 16 in Quality of Life in Hand Eczema Questionnaire (QOLHEQ) | -13.36 ± 21.222 | -38.70 ± 23.920 |
WPAI + CIQ is a self-administered instrument used to capture the impairment to work productivity/classroom impairment and activity due to atopic hand and foot dermatitis. The WPAI+CIQ yields 4 types of scores: absenteeism, presenteeism, work/classroom productivity loss and activity impairment. All scores range from 0 to 100% with 100% indicating total work/classroom productivity impairment and 0 no impairment at all.
| Score on a scale | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Mean Change From Baseline to Week 16 in Work Productivity and Impairment (WPAI) and Classroom Impairment Questionnaire (CIQ) | -21.26 ± 3.761 | -36.39 ± 3.649 |
| Percentage of participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 16 | 74.2 | 65.7 |
| Milligrams per Liter (mg/L) | Dupilumab 300 mg - Adult Participants | Dupilumab 200 mg - Adolescent Participants | Dupilumab 300 mg - Adolescent Participants |
|---|---|---|---|
| Week 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Week 16 | 51.2 ± 22.0 | 34.0 ± 10.7 | 37.1 ± 15.9 |
| Week 28 | 7.37 ± 25.0 | 60.0 ± 84.9 | 7.54 ± 16.9 |
| Participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Treatment-Boosted Response | 0 | 0 |
| Treatment-Emergent Response | 1 | 8 |
| Participants | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Low (<1,000) | 1 | 8 |
| Moderate (1,000 to 10,000) | 0 | 0 |
| High (>10,000) | 0 | 0 |
Collected over From first dose to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Matching Placebo | 0/66 (0%) | 1/66 (1.5%) | 34/66 (51.5%) |
| Dupilumab Q2W | 0/67 (0%) | 3/67 (4.5%) | 33/67 (49.3%) |
| Event | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| AppendicitisInfections and infestations | 1/66 | 0/67 |
| Post procedural infectionInfections and infestations | 0/66 | 1/67 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/66 | 1/67 |
| Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/66 | 1/67 |
| DizzinessNervous system disorders | 0/66 | 1/67 |
| SyncopeNervous system disorders | 0/66 | 1/67 |
| Event | Matching Placebo | Dupilumab Q2W |
|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 16/66 | 6/67 |
| NasopharyngitisInfections and infestations | 8/66 | 16/67 |
| COVID-19Infections and infestations | 14/66 | 11/67 |
| Upper respiratory tract infectionInfections and infestations | 3/66 | 7/67 |
| Blood creatine phosphokinase increasedInvestigations | 1/66 | 4/67 |
| Age, Continuous(Years) | Matching Placebo | Dupilumab Q2W | Total |
|---|---|---|---|
| Mean | 33.4 ± 14.66 | 35.8 ± 17.07 | 34.6 ± 15.9 |
| Sex: Female, Male(Participants) | Matching Placebo | Dupilumab Q2W | Total |
|---|---|---|---|
| Female | 38 | 45 | 83 |
| Male | 28 | 22 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Matching Placebo | Dupilumab Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 63 | 64 | 127 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Matching Placebo | Dupilumab Q2W | Total |
|---|---|---|---|
| White | 53 | 53 | 106 |
| Black or African American | 4 | 3 | 7 |
| Asian | 8 | 9 | 17 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Other | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Apr 2021 to primary completion in Aug 2022, 16 months.
Results were first posted in Dec 2023, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab